Revolution Medicines · 1 month ago
Executive Director, Global Pricing Strategy and Operations
United States
Full-time
Remote
Director/Executive
$256K/yr - $320K/yr
15+ years expRevolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies. The Executive Director, Global Pricing will be responsible for building the global pricing function and strategy to support the commercial launch and long-term value optimization of the company’s innovative therapies.
Health CareLife ScienceMedical
Responsibilities
Design and implement the company’s first global pricing framework, policies, SOPs, governance committees, and approval workflows
Develop global pricing infrastructure including systems, tools, analytics platforms, dashboards, and documentation standards
Define the operating model for pricing interactions and partnering with future regional teams
Create foundational IRP, net-price management tools and processes
Develop portfolio wide pricing principles, policies and advance best practices to optimize value recognition by stakeholders globally
Establish a compliant global pricing governance model with clear decision-rights and escalation pathways
Ensure adherence to global regulatory requirements, including national pricing rules, IRP risks, anti-trust considerations
Implement controls to monitor price changes, discounting, contracting, and tender strategy
Lead strategic initiatives related to product launches, price optimization and analytics
Engage with Regions to incorporate payer, policy insights and global trends into enterprise pricing strategies
Develop and maintain strong business relationships with key functions with a focus on Clinical, Commercial, Regulatory, and Finance
Collaborate with regional pricing teams, IT and Finance to ensure data quality, system integrity and actionable insights
Coordinate with regions to align on policy and legislation risks that could impact global pricing strategies and tactics
Qualification
Required
Bachelor's degree required; advanced degree in Finance, Pharmacy, Health Economics, Life Sciences, or Business preferred (e.g., PharmD, PhD, MBA)
Minimum 15+ years of progressive leadership in market access, pricing, and/or finance within the biopharma industry
Demonstrated ability to build a new Pricing function to support a Global Market Access commercialization strategy
Deep understanding of global payer systems and HTA processes
Experience designing and implementing global pricing strategy, including value-based pricing, launch sequencing, and reference pricing mitigation
Proven ability to work cross-functionally and influence executive leadership in a dynamic, resource-constrained, early-stage company
Preferred
Prior experience with pharmaceutical pricing strategy in U.S. and global markets
Strong understanding of global health systems, health policy, pricing regulations, reimbursement environments and familiarity with key U.S. and Global price policy trends
Familiarity with rare disease, or oncology product launches
Strong executive presence, with the ability to clearly articulate complex pricing issues to both internal and external stakeholders
Experience building or scaling global pricing function in a pre-commercial or newly commercial biotech company
Benefits
Competitive cash compensation
Robust equity awards
Strong benefits
Significant learning and development opportunities
Company
Revolution Medicines
Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.
501-1000 employees
H1B Sponsorship
Revolution Medicines has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (13)
2024 (18)
2023 (15)
2022 (8)
2021 (1)
2020 (2)
Funding
Current Stage
Public CompanyTotal Funding
$2.25BKey Investors
Royalty PharmaBoxer CapitalNextech Invest
2025-06-24Post Ipo Debt· $250M
2024-12-02Post Ipo Equity· $750M
2023-03-02Post Ipo Equity· $323.6M
Leadership Team
Luan Wilfong
Chief Human Resources Officer
Steve Kelsey
President
Recent News
Pharmaceutical Technology
2026-01-13
Company data provided by crunchbase